Following myocardial infarction (MI), patients with diabetes have worse clinical outcome compared to individuals with normal glucose metabolism, including increased rate of recurrent events and higher cardiovascular and all-cause mortality.1, , –4 This adverse outcome is particularly pronounced in insulin-treated patients.5 National and international guidelines recommend aggressive management of dyslipidaemia and hypertension in high vascular risk diabetes patients, though the same guidelines note that a gap in the knowledge exists as to appropriate glycaemic management in this population.6 This evidence concerns the gene INS and myocardial infarction.